AI Verdict
NBIX has stronger fundamentals based on our AI analysis.
NBY vs NBIX Fundamental Comparison
| Metric | NBY | NBIX |
|---|---|---|
| Revenue | $521,000.0 | $2.9B |
| Net Income | $-22.1M | $478.6M |
| Net Margin | -4,249.7% | 16.7% |
| ROE | N/A | 14.7% |
| ROA | -245.1% | 10.3% |
| Current Ratio | 7.60x | 3.39x |
| Debt/Equity | N/A | 0.00x |
| EPS | $0.76 | $4.67 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
NBY vs NBIX: Frequently Asked Questions
Is NBY or NBIX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), NBIX has stronger fundamentals. NBY is rated STRONG SELL (95% confidence) while NBIX is rated STRONG BUY (88% confidence). This is not investment advice.
How does NBY compare to NBIX fundamentally?
NovaBay Pharmaceuticals, Inc. has ROE of N/A vs NEUROCRINE BIOSCIENCES INC's 14.7%. Net margins are -4,249.7% vs 16.7% respectively.
Which stock pays higher dividends, NBY or NBIX?
NBY has a dividend yield of N/A or no dividend while NBIX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in NBY or NBIX for long term?
For long-term investing, consider that NBY has STRONG SELL rating with 95% confidence, while NBIX has STRONG BUY rating with 88% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about NBY vs NBIX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For NBY vs NBIX, the AI consensus favors NBIX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.